{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:41:42Z","timestamp":1760647302585},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The safety of immunosuppressive regimens is influenced by the induction agent, maintenance drug combination, and prophylactic strategy for cytomegalovirus (CMV) infection. Herein, this safety analysis compares rabbit antithymocyte globulin (r-ATG) or basiliximab (BAS) combined with everolimus (EVR) versus BAS combined with mycophenolate sodium (MPS) in kidney transplant recipients receiving tacrolimus, prednisone, and preemptive CMV therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this single-center, prospective, randomized study, adverse events (AEs), serious AEs (SAEs), viral infections, laboratory abnormalities, dose reductions, and temporary or permanent discontinuation of the immunosuppressant were compared among patients receiving r-ATG\/EVR (n = 85), BAS\/EVR (n = 102), and BAS\/MPS (n = 101).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 2741 AEs and 344 SAEs were observed. There were no differences in the proportion of patients with at least one AE (96% versus 98% versus 96%, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). The proportion of patients with at least one SAE was highest in the BAS\/MPS group (33% versus 48% versus 69%, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). This difference was due primarily to a high incidence of CMV infection in the BAS\/MPS group (4.7% versus 10.8% versus 37.6%, respectively). The incidence of mild\/moderate abnormalities in creatinine, cholesterol, and triglyceride levels was higher in both EVR groups. The cumulative freedom from dose reduction or treatment discontinuation due to an AE was higher in both EVR groups than in the BAS\/MPS group (89.2% versus 92.8% versus 76.3%, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). There was no difference in the incidence of biopsy-confirmed acute rejection (9.4% versus 18.6 versus 15.8%, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.403).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This analysis suggests that r-ATG induction combined with EVR is associated with a comparable incidence of acute rejection, lower incidence of CMV infection, and fewer changes in initial immunosuppressive regimen due to AEs in kidney transplant recipients receiving tacrolimus, prednisone, and preemptive CMV therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000790","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T05:02:34Z","timestamp":1595480554000},"page":"811-820","source":"Crossref","is-referenced-by-count":6,"title":["Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses"],"prefix":"10.1097","volume":"42","author":[{"given":"Tamiris A.","family":"Miranda","sequence":"first","affiliation":[{"name":"Division of Nephrology, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, S\u00e3o Paulo, Brazilo; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia R.","family":"Felipe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, S\u00e3o Paulo, Brazilo; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato H. N.","family":"Santos","sequence":"additional","affiliation":[{"name":"HCor Research Institute, Hospital do Cora\u00e7\u00e3o, S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose O.","family":"Medina Pestana","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, S\u00e3o Paulo, Brazilo; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio","family":"Tedesco-Silva Junior","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hospital do Rim, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, S\u00e3o Paulo, Brazilo; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transpl."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marc\u00e9n","year":"2009","journal-title":"Drugs."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/AOT.895664","article-title":"Multinational evaluation of mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus utilization","volume":"21","author":"Gardiner","year":"2016","journal-title":"Ann Transpl."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transpl."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transpl."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transpl."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation","volume":"14","author":"Knoll","year":"2003","journal-title":"J Am Soc Nephrol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.1733","article-title":"Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms","volume":"23","author":"Brennan","year":"2013","journal-title":"Rev Med Virol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trre.2014.01.001","article-title":"The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients","volume":"28","author":"Roman","year":"2014","journal-title":"Transpl Rev."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"e13106","DOI":"10.1111\/tid.13106","article-title":"Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy","volume":"21","author":"Felipe","year":"2019","journal-title":"Transpl Infect Dis."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2019.10.045","article-title":"Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: impact of mTOR inhibitors","volume":"469","author":"Petrara","year":"2020","journal-title":"Cancer Lett."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/FTD.0b013e31816b9063","article-title":"Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges","volume":"30","author":"Christians","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transpl."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:15:50Z","timestamp":1692051350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000790","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}